# US 2005/0232906 A1 · Adjuvant preparation for the induction of specific immunity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0232906 A1
- Document ID: US20050232906A1
- Status: Published application
- Kind: A1
- Application number: 11/093,269
- Filed: 2005-03-29
- Published: 2005-10-20
- Earliest claimed: 2000-05-31
- Assignees: Board of Regents, The University of Texas System
- Inventors: Isaiah Fidler; Zhongyun Dong; Weixin Lu
- Web page: https://patentgrep.com/patent/US20050232906A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/0011: {Cancer antigens}
- A61P 35/00: Antineoplastic agents
- C12N 5/0601: {Invertebrate cells or tissues, e.g. insect cells; Culture media therefor}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/5152: {Tumor cells}
- A61K 2039/5156: {expressing foreign proteins}
- A61K 2039/5158: {Antigen-pulsed cells, e.g. T-cells}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/55533: {IL-2}
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are methods and compositions useful in the recruitment, activation and initiation of proliferation of immune cells. The instant invention relates to the discovery that specific insect cells and insect cell compositions exhibit adjuvant properties. The added benefit of this system is that the insect cells utilized may be transformed with an expression system and thus proteins may be introduced into the composition through direct protein expression by the cells. The claimed compositions and methods are particularly relevant in anti-tumor and cancer therapy. Of specific interest is the ability of the compositions of the invention to elicit a response that controls not only the primary tumor but also any metastatic cells or metastatic tumors which subsequently arise.

## Claims

### Claim at position 1

1-132. (canceled)

### Claim 133

A method of inhibiting cancer growth in a host having a cancer comprising:
(a) isolating cancer cells from said host;
(b) rendering said cancer cells inactive;
(c) reintroducing said inactivated cancer cells into said host in a pharmaceutical composition, said pharmaceutical composition further comprising an insect cell composition.

### Claim 134 (depends on 133)

The method of claim 133, wherein said insect cell composition further comprises an immunomodulator.

### Claim 135 (depends on 134)

The method of claim 134, wherein said immunomodulator is IFNα.

### Claim 136 (depends on 134)

The method of claim 134, wherein said immunomodulator is IL-2.

### Claim 137 (depends on 133)

The method of claim 133, wherein said cancer is localized.

### Claim 138 (depends on 133)

The method of claim 133, wherein said cancer is metastatic.

### Claim 139 (depends on 140)

The method of claim 140, wherein said exogenous DNA is a baculovirus expression vector.

### Claim 140 (depends on 133)

The method of claim 133, wherein said insect cell composition comprises an exogenous DNA.

### Claim 141 (depends on 140)

The method of claim 140, wherein said exogenous construct encodes an immunomodulator.

### Claim at position 11

142-194. (canceled)
